Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43693   clinical trials with a EudraCT protocol, of which   7245   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    10,192 result(s) found. Displaying page 1 of 510.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-004506-18 Sponsor Protocol Number: LYMRIT-37-07 Start Date*: 2018-06-13
    Sponsor Name:Nordic Nanovector ASA
    Full Title: A phase 2 open-label study of Betalutin in combination with rituximab in patients with relapsed/refractory follicular lymphoma (Archer-1)
    Medical condition: Follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003461-17 Sponsor Protocol Number: 71272 Start Date*: 2020-01-07
    Sponsor Name:Amsterdam UMC, location VUmc
    Full Title: Pathophysiological relevance of IRON deficiency and related mitochondrial dysfunction in Heart Failure with Preserved Ejection Fraction (IRON-HFpEF)
    Medical condition: Heart failure with preserved ejection fraction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002078-30 Sponsor Protocol Number: NL70122.078.20 Start Date*: 2020-06-19
    Sponsor Name:Erasmus MC
    Full Title: Autoimmune epilepsy Modulated by IVIg – effects on Cortical Excitability, the AMICE study
    Medical condition: Auto-immune epilepsy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010093-38 Sponsor Protocol Number: HyRec Start Date*: 2012-08-15
    Sponsor Name:Dekan of the Medical Faculty of the University Erlangen-Nuremberg; Prof. Dr. Dr. h. c. Jürgen Schüttler
    Full Title: Multi-institutional Phase I/II Study: Neoadjuvant chemoradiation with 5-FU (or capecitabine) and oxaliplatin combined with deep regional hyperthermia in locally advanced or recurrent rectal cancer
    Medical condition: Locally advanced primary or locally recurrent rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038051 Rectal cancer stage IV PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038046 Rectal cancer recurrent PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000449-11 Sponsor Protocol Number: EP250567 Start Date*: 2012-03-01
    Sponsor Name:Eero Pesonen
    Full Title: Heparin dose (300 IU/kg vs. 600 IU/kg) in coroanry artery bypass grafting
    Medical condition: Patients undergoing elective coronary artery bypass grafting
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10068176 Coronary artery bypass graft LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000550-60 Sponsor Protocol Number: V7/22032018 Start Date*: 2014-01-17
    Sponsor Name:Medizinische Universität Wien, Klinische Abteilung für Nephrologie und Dialyse, Universitätsklinik für Innere Medizin 3
    Full Title: Pulsed oral sirolimus in autosomal dominant polycystic kidney disease
    Medical condition: Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and uncontrolled proliferation of innumerable epithelial-lined cysts that stem from renal...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002226-23 Sponsor Protocol Number: 2013-002226-23 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Bergen, Department of Global Public Health and Primary Care
    Full Title: Efficacy of Pain Treatment on Depression in Patients with Dementia. A Randomized Clinical Trial of Efficacy
    Medical condition: Depression Pain Dementia
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005279-18 Sponsor Protocol Number: RG_11-164 Start Date*: 2012-02-08
    Sponsor Name:University of Birmingham
    Full Title: A RandoMised study of best Available therapy versus JAK Inhibition in patients with high risk Polycythaemia Vera or Essential Thrombocythaemia who are resistant or intolerant to HydroxyCarbamide.
    Medical condition: Polycythaemia vera Essential Thrombocythaemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036057 Polycythaemia vera PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-015316-17 Sponsor Protocol Number: 01AneInt2009 Start Date*: 2017-11-17
    Sponsor Name:Oslo Universitetssykehus - Rikshospitalet
    Full Title: Perioperativ administrasjon av pregabalin ved laparoskopisk living donor nefrektomi (L-LDN) - et adjuvans til peroral analgetisk behandling - en randomisert kontrollert studie
    Medical condition: Hensikten med studien er å undersøke om perioperativ administrasjon av pregabalin vil redusere postoperativ smerte og forbruket av intravenøse opioider postoperativt sammenliknet med dagens standar...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10054711 Postoperative pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002255-42 Sponsor Protocol Number: MK-3222-010 Start Date*: 2013-01-10
    Sponsor Name:Sun Pharma Global FZE
    Full Title: A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optiona...
    Medical condition: Moderate-to-Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-000919-22 Sponsor Protocol Number: OMB114578 Start Date*: 2011-09-14
    Sponsor Name:University of Liverpool [...]
    1. University of Liverpool
    2. Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trus
    Full Title: RIAltO: A Randomised Investigation of Alternative Ofatumumab-containing regimens in less fit patients with CLL
    Medical condition: Chronic Lymphocytic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008993 Chronic lymphoid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-004787-62 Sponsor Protocol Number: DUS Start Date*: 2014-11-26
    Sponsor Name:SOD Anestesia e Terapia Intensiva, DAI Oncologia, AOU Careggi, Firenze
    Full Title: Evaluation of muscle function recovery after deep neuromuscular blockade by acceleromyography of the adductor pollicis or diaphragmatic echography: comparison between sugammadex and neostigmine
    Medical condition: Muscle function recovery post neuromuscoular blockade
    Disease: Version SOC Term Classification Code Term Level
    19.1 10042613 - Surgical and medical procedures 10057286 Neuromuscular blockade reversal PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005095-28 Sponsor Protocol Number: IRST186.02 Start Date*: 2015-04-16
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: Olaparib as salvage treatment for cisplatin-resistant germ cell tumor.
    Medical condition: cisplatin-resistant germ cell tumor
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004978-34 Sponsor Protocol Number: RBHP2017BACHOUMAS Start Date*: 2018-12-04
    Sponsor Name:CHU de Clermont-ferrand
    Full Title: Efficacy of Testosterone gel to restore normal serum values of testosterone during the acute phase of critical illness in adult ICU patients. An open-label parallel randomized controlled pilot study
    Medical condition: - Hypermetabolism in ICU, loss of muscle mass and functional disability after ICU - ICU acquired hypogonadism - Treatment with testosterone gel in ICU
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000724-10 Sponsor Protocol Number: 60978 Start Date*: 2018-07-04
    Sponsor Name:Academic Medical Center
    Full Title: Targeting esophageal cancer with HDL nanoparticles: an imaging study
    Medical condition: Primary esophageal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001563-74 Sponsor Protocol Number: PHRCN2018/LEVOHEARTSHOCK-LEVY/YB Start Date*: 2020-07-24
    Sponsor Name:CHRU de Nancy
    Full Title: Effect of early use of levosimendan versus placebo on top of a conventional strategy of inotrope use on a combined morbidity-mortality endpoint in patients with cardiogenic shock. LevoHeartShock St...
    Medical condition: Cardiogenic shock
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007625 Cardiogenic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004419-35 Sponsor Protocol Number: GN13RH410 Start Date*: 2015-03-18
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: Inhibition of Co-Stimulation in Rheumatoid Arthritis
    Medical condition: Rheumatoid Arthritis: patients who are dual ACPA and HLA-DR4 positive
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-002597-12 Sponsor Protocol Number: 013-IRCC-10IIS-16 Start Date*: 2017-03-09
    Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS
    Full Title: A PHASE II TRIAL OF RECHALLENGE WITH PANITUMUMAB DRIVEN BY RAS CLONAL-MEDIATED DYNAMIC OF RESISTANCE. THE CHRONOS TRIAL.
    Medical condition: METASTATIC COLORECTAL CANCER
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10001172 Adenocarcinoma of colon stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004299-37 Sponsor Protocol Number: CA209-8U4 Start Date*: 2019-01-24
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: NIVOLUMAB plus IPILIMUMAB and TEMOZOLOMIDE in combination in microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC): the MAYA study.
    Medical condition: Microsatellite stable (MSS), MGMT-silenced metastatic colorectal carcinoma (mCRC).
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000580-90 Sponsor Protocol Number: ASSTBS-ONCO-ACACIA-18 Start Date*: 2018-06-20
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: Multicenter randomized open-label phase III trial of Adjuvant Chemotherapy vs. observation or mitotane after primary surgical resection of localized
    Medical condition: localized Adrenocortical CarcInomA with high risk of recurrence
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001388 Adrenocortical carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA